Sugi Predict

Sugi Predict / Compounds / SCHEMBL15845792

SCHEMBL15845792

SCHEMBL15845792

COc1cc(Br)cc2c(=O)[nH]cnc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 8/20 0.47
▸ PIM1 P11309 4/20 0.47
▸ PIM3 Q86V86 2/20 0.47
▸ CHEK1 O14757 2/20 0.47
▸ AKT1 P31749 1/20 0.47
▸ FLT3 P36888 1/20 0.47
▸ SRC P12931 2/20 0.47
▸ BCL2 P10415 1/20 0.44
▸ MCL1 Q07820 1/20 0.44
▸ CDC7 O00311 1/20 0.43
▸ CSNK2A2 P19784 1/20 0.43
▸ CSNK2B P67870 1/20 0.43
▸ CSNK2A1 P68400 1/20 0.43
▸ CSNK2A3 Q8NEV1 1/20 0.43
▸ PIM2 Q9P1W9 1/20 0.43
▸ NQO2 P16083 2/20 0.39
▸ EGFR P00533 1/20 0.38
▸ RPS6KA3 P51812 2/20 0.37
▸ ABL1 P00519 2/20 0.37
▸ AURKA O14965 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28036199 0.98 PARP1 (0.46) PARP1PIM1PIM3CHEK1AKT1
SCHEMBL15859686 0.83 PARP1 (0.66) PARP1PIM1CHEK1SRCBCL2
SCHEMBL11408922 0.83 PARP1 (0.49) PARP1PIM1CHEK1SRCBCL2
SCHEMBL24392583 0.81 PARP1 (0.47) PARP1PIM1CHEK1SRCBCL2
SCHEMBL15845811 0.81 SRC (0.50) PARP1PIM1CHEK1SRCBCL2
SCHEMBL29588853 0.81 PARP1 (0.47) PARP1PIM1CHEK1SRCBCL2
Hydrochloric Acid SCHEMBL28036158 0.80 SRC (0.49) PARP1PIM1CHEK1SRCBCL2
SCHEMBL16112933 0.79 PARP1 (0.70) PARP1PIM1PIM3CHEK1AKT1
SCHEMBL31380182 0.78 PIM1 (0.54) PARP1PIM1PIM3CHEK1AKT1
SCHEMBL15845970 0.77 PARP1 (0.39) PARP1PIM1PIM3CHEK1AKT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12617789-B2 Small molecular inhibitors of NF-κb inducing kinase JANSSEN PHARMACEUTICA NV (BE) 2026-05-05 — — US disclosed
EP-4467199-A2 SMALL MOLECULE INHIBITORS OF NF-KB INDUCING KINASE JANSSEN Pharmaceutica NV (BE) 2024-11-27 — — EP disclosed
CN-118908957-A Small molecule inhibitors of NF- κB induced kinase 詹森药业有限公司 2024-11-08 — — CN disclosed
EP-3976597-B1 SMALL MOLECULE INHIBITORS OF NF-KB INDUCING KINASE JANSSEN PHARMACEUTICA NV (BE) 2024-08-28 — — EP disclosed
CN-114222737-B Small molecule inhibitors of NF- κB induced kinase 詹森药业有限公司 2024-07-26 — — CN disclosed
US-20240199605-A1 SMALL MOLECULAR INHIBITORS OF NF-kB INDUCING KINASE JANSSEN PHARMACEUTICA NV (BE) 2024-06-20 — — US disclosed
US-11827634-B2 Small molecule inhibitors of NF-kB inducing kinase JANSSEN PHARMACEUTICA NV (BE) 2023-11-28 — — US disclosed
US-20230080834-A1 SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE JANSSEN PHARMACEUTICA NV (BE) 2023-03-16 — — US disclosed
EP-3976597-A1 SMALL MOLECULE INHIBITORS OF NF-KB INDUCING KINASE Janssen Pharmaceutica NV (BE) 2022-04-06 — — EP disclosed
CN-114222737-A Small molecule inhibitor of NF-kB induced kinase 詹森药业有限公司 2022-03-22 — — CN disclosed
US-9656971-B2 COMT inhibitors HOFFMANN-LA ROCHE INC. (US) 2017-05-23 — — US disclosed
US-9656971-B2 COMT inhibitors HOFFMANN-LA ROCHE INC. (US) 2017-05-23 — — US disclosed
EP-2938600-B1 COMT INHIBITORS HOFFMANN LA ROCHE (CH) 2017-01-25 — — EP disclosed
EP-2938600-B1 COMT INHIBITORS HOFFMANN LA ROCHE (CH) 2017-01-25 — — EP disclosed
US-20160002177-A1 COMT INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2016-01-07 — — US disclosed
US-20160002177-A1 COMT INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2016-01-07 — — US disclosed
US-20160002177-A1 COMT INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2016-01-07 — — US disclosed
EP-2938600-A1 COMT INHIBITORS F. Hoffmann-La Roche AG (CH) 2015-11-04 — — EP disclosed
WO-2014102233-A1 COMT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2014-07-03 — — WO disclosed
WO-2014102233-A1 COMT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2014-07-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160002177-A1 COMT INHIBITORS COMT, PNMT, SLC6A3 PARP1 2456/4885PIM1 1480/4885PIM3 1794/4885
US-20230080834-A1 SMALL MOLECULE INHIBITORS OF NF-kB INDUCING KINASE NFKBIA, IKBKB, NFRKB PARP1 944/4885PIM1 327/4885PIM3 822/4885
US-11827634-B2 Small molecule inhibitors of NF-kB inducing kinase NFKBIA, IKBKB, NFRKB PARP1 944/4885PIM1 327/4885PIM3 822/4885
US-12617789-B2 Small molecular inhibitors of NF-κb inducing kinase IRAK3, IKBKB, IKBKG PARP1 1728/4885PIM1 776/4885PIM3 719/4885
US-20240199605-A1 SMALL MOLECULAR INHIBITORS OF NF-kB INDUCING KINASE NFKBIA, IKBKB, IKBKE PARP1 900/4885PIM1 363/4885PIM3 877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.